ClinicalTrials.gg
RecruitingNCT03233646Updated Feb 4, 2026

Retinal Imaging in Neurodegenerative Disease

An observational study in Alzheimer's Disease, Mild Cognitive Impairment and Parkinson's Disease, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Duke University · Observational

How we know

From the registry’s dates

  • Started Jul 2017; still recruiting 9 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Alzheimer Disease by Duke University — 4 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · Duke University.

Started
2017
with 2 others
Observational
5 of 15
2 open now
Registered
8th of 15
by date

Among the 15 studies in Alzheimer Disease by Duke University, this one is one of 3 that started in 2017, is one of 5 observational ones, and was the 8th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 15 studies in Alzheimer Disease by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Alzheimer Disease by Duke University, or all of them as a file.
02

Study summary

This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.

Read the detailed description

Using a multidisciplinary approach, this study aims to yield new insight into the vascular and structural pathophysiology of neurodegenerative disease. The investigators propose to develop and evaluate imaging biomarkers from OCT, OCTA, and UWF fundus photos to assess the structure and function of the retinal and choroidal microvasculature and structure in these individuals.

The investigators hypothesize that microvascular and structural network alterations in the retina and choroid may mirror and possibly precede changes in the cerebral microcirculation seen in these neurodegenerative diseases. Using advanced image analysis and machine learning techniques, the investigators aim to evaluate markers of reduced capillary blood flow and non-perfusion in the superficial retinal vascular plexus and choriocapillaris imaged using OCT and OCTA, in a resolution not previously possible, that would complement already established retinal structural markers and increase their sensitivity and specificity in the earlier detection of these neurodegenerative diseases.

This study looks to provide a proof of concept for retinal and choroidal imaging-based microvascular and structural biomarkers as an effective screening tool for neurodegenerative disease, particularly during in cognitive aging.

The protocol for this study was amended and the record was updated accordingly.

03

Conditions studied

  • Alzheimer's Disease
  • Mild Cognitive Impairment
  • Parkinson's Disease
  • Multiple Sclerosis
  • Huntington Disease
  • Lewy Body Dementia
  • Frontotemporal Dementia
  • Amyotrophic Lateral Sclerosis (ALS)
  • APOE-4 Positive
  • Traumatic Brain Injury
  • Concussion
  • Post-Traumatic Stress Disorder
  • Down Syndrome
  • Neuro-Degenerative Disease
  • Normal Cognition

Keywords

  • OCT angiography (OCTA)
  • Optical Coherence Tomography (OCT)
  • Vessel Density
  • Superficial Capillary Plexus
  • Retinal microvasculature
  • Scanning Laser Ophthalmoscopy
  • Ultra-widefield (UWF) Imaging
  • Perfusion Density
  • Retinal Nerve Fiber Layer
  • Ganglion Cell Inner Plexiform Layer
  • Choroidal Vascularity Index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Neurology Clinics and the community.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with neurodegenerative disease ((MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)
  • Adults without neurodegenerative disease

Exclusion criteria

Exclusion Criteria:

  • Inability to cooperate with or complete testing or other neurologic or age- related ocular conditions that would impact image acquisition.
  • Eyes that have had intraocular surgery, other than cataract surgery.

If two eyes satisfy the inclusion criteria, both eyes will be included in the study. If one eye satisfies the inclusion criteria, the eye that qualifies will be included in the study.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case

    Patients with (MCI, PD, AD, FTD, DLB, ALS, MS, HD, TBI, concussion, PTSD and other neurodegenerations as well as Down Syndrome)

    Device: Retinal and Choroidal Imaging

  • Controls

    Controls will be recruited from the relatives/attendants of study participants or will be patients themselves and will not have a neurodegenerative disease diagnosis.

    Device: Retinal and Choroidal Imaging

Interventions

  • DeviceRetinal and Choroidal Imaging

    Non-invasive OCT, OCTA, and UWF fundus photography of retina

06

What researchers measure

Primary outcomes

  1. Change in ganglion cell-inner plexiform layer (GCIPL) thickness

    Ganglion cell inner plexiform layer thickness as measured on optical coherence tomography scan of macula

    Time frame: Baseline, 1 year

  2. Change in retinal nerve fiber layer (RNFL) thickness

    Retinal nerve fiber layer thickness as measured on optical coherence tomography scan of macula

    Time frame: Baseline, 1 year

  3. Change in central subfield thickness (CST)

    Central subfield thickness as measured on optical coherence tomography scan of macula

    Time frame: Baseline, 1 year

  4. Change in choroidal vascularity index (CVI)

    Choroidal vascularity index as measured using the COIN software in 1500 um area centered on the fovea

    Time frame: Baseline, 1 year

  5. Change in foveal avascular zone (FAZ) area

    Foveal avascular zone area as measured in the superficial capillary plexus on 3mm optical coherence tomography angiography scan of the macula

    Time frame: Baseline, 1 year

  6. Change in average perfusion density (PD)

    Average perfusion density as measured in the ETDRS 3mm and 6mm circle and rings on optical coherence tomography angiography scan of the macula

    Time frame: Baseline, 1 year

  7. Change in average vessel density (VD)

    Average vessel density as measured in the ETDRS 3mm and 6mm circle and rings on optical coherence tomography angiography scan of the macula

    Time frame: Baseline, 1 year

  8. Change in average capillary perfusion density (CPD)

    Capillary perfusion density as measured on peripapillary 4.5mm optical coherence tomography angiography scan

    Time frame: Baseline, 1 year

  9. Change in average capillary flux index (CFI)

    Capillary flux index as measured on peripapillary 4.5mm optical coherence tomography angiography scan

    Time frame: Baseline, 1 year

Secondary outcomes

  1. Change in retinal vessel tortuosity

    Retinal vessel tortuosity measured on ultra-widefield scanning laser ophthalmoscopy image using VAMPIRE software

    Time frame: Baseline, 1 year

  2. Change in retinal vessel width gradient

    Retinal vessel width gradient measured on ultra-widefield scanning laser ophthalmoscopy image using VAMPIRE software

    Time frame: Baseline, 1 year

  3. Change in retinal vessel fractal dimension

    Retinal vessel fractal dimension measured on ultra-widefield scanning laser ophthalmoscopy image using VAMPIRE software

    Time frame: Baseline, 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zhao W, Robbins CB, Grewal DS, Patel H, Soundararajan S, Liu AJ, Johnson KG, Agrawal R, Petrella JR, Stinnett SS, Parker D, Fekrat S. Correlating retinal and choroidal vascular parameters with volumetric MRI in Alzheimer's disease and amnestic mild cognitive impairment. BMC Ophthalmol. 2025 Jul 1;25(1):365. doi: 10.1186/s12886-025-04157-x. PubMed 40598011 ↗
  • Robbins CB, Akrobetu D, Ma JP, Stinnett SS, Soundararajan S, Liu AJ, Johnson KG, Grewal DS, Fekrat S. ASSESSMENT OF RETINAL MICROVASCULAR ALTERATIONS IN INDIVIDUALS WITH AMNESTIC AND NONAMNESTIC MILD COGNITIVE IMPAIRMENT USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2022 Jul 1;42(7):1338-1346. doi: 10.1097/IAE.0000000000003458. PubMed 35723922 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Dec 2026, 113 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 113 months is above that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2017
First posted
Jul 28, 2017
StartActual
Jul 20, 2017
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03233646
Lead sponsor
Duke University
Collaborators
University of Edinburgh in Scotland, Tan Tock Seng Hospital in Singapore, Queens University of Belfast United Kingdom
Responsible party
Sponsor
First posted
Jul 28, 2017
Start date
Jul 20, 2017
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 4, 2026

Study contacts

Sharon Fekrat, MD FACS FASRS
Contact
imind@duke.edu
919-681-3937
Sharon Fekrat, MD FACS FASRS
principal investigator · Duke University
Dilraj Grewal, MD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion